Show simple item record

dc.contributor.authorDelaloge, S
dc.contributor.authorConte, P
dc.contributor.authorIm, S
dc.contributor.authorSenkus-Konefka, E
dc.contributor.authorXu, B
dc.contributor.authorDomchek, S
dc.contributor.authorMasuda, N
dc.contributor.authorLi, W
dc.contributor.authorTung, N
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorWu, W
dc.contributor.authorGoessl, C
dc.contributor.authorRunswick, S
dc.contributor.authorRobson, M
dc.date.accessioned2017-11-23T21:45:54Z
dc.date.available2017-11-23T21:45:54Z
dc.date.issued2017-09
dc.identifier.citation243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdx365.006
dc.identifier.urihttp://hdl.handle.net/10541/620703
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.006/4108472/243PDOlympiAD-Further-efficacy-outcomes-inen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentBreast Cancer Group, Institut Gustave Roussy, Villejuif, Franceen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record